Encompass Health

Encompass Health Forecasts $6.465B in 2026 Revenue Amid Capacity Expansion and Regulatory Adaptation

Encompass Health shares surge 14.46% after hours on Q4 earnings beat and 2026 revenue guidance.

EncompassHealth

Encompass Health: Barclays Maintains Overweight Rating, Raises PT to $153.

Encompass Health shares surge 20.53% premarket after Q4 results beat estimates, driving optimism with 14.9% adjusted EBITDA growth and strong 2026 guidance.

Encompass Health Corporation shares rise over 20% pre-market, currently trading at $120.00.

Catalyst<ul> <li>Most analysts rate EHC Buy, showing broad institutional optimism.</li> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for EHC.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Fund flows are negative across most buckets, indicating a lack of investor confidence.</li> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li></ul>

Key Factors

Encompass Health (EHC) reported Q4 2025 adjusted EPS of $1.46, beating estimates by 24.8% and driving a 20.49% after-hours stock surge.EHC provided 2026 revenue guidance of $6.365–$6.465 billion and adjusted EBITDA of $1.34–$1.38 billion, exceeding Wall Street expectations.EHC added 517 inpatient rehabilitation beds in 2025 through eight new hospitals and bed expansions, supporting capacity growth.

EHC News